Biora Therapeutics, Inc. (NASDAQ:BIOR – Free Report) – Equities research analysts at Zacks Small Cap reduced their FY2023 earnings per share (EPS) estimates for shares of Biora Therapeutics in a research report issued on Tuesday, November 14th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of ($4.85) per share for the year, down from their previous forecast of ($4.60). The consensus estimate for Biora Therapeutics’ current full-year earnings is ($4.35) per share.
Biora Therapeutics (NASDAQ:BIOR – Get Free Report) last issued its quarterly earnings results on Monday, August 14th. The company reported ($1.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.13.
Biora Therapeutics Stock Performance
Biora Therapeutics stock opened at $1.34 on Thursday. The company’s fifty day moving average price is $2.11 and its 200 day moving average price is $3.16. Biora Therapeutics has a 1 year low of $1.26 and a 1 year high of $7.68. The stock has a market capitalization of $18.60 million, a P/E ratio of -0.14 and a beta of 1.22.
Institutional Trading of Biora Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp increased its stake in Biora Therapeutics by 324.4% during the first quarter. State Street Corp now owns 439,347 shares of the company’s stock worth $510,000 after acquiring an additional 335,827 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Biora Therapeutics during the 1st quarter worth about $431,000. Geode Capital Management LLC lifted its position in Biora Therapeutics by 83.3% in the second quarter. Geode Capital Management LLC now owns 80,812 shares of the company’s stock valued at $311,000 after buying an additional 36,720 shares during the last quarter. Millennium Management LLC increased its position in shares of Biora Therapeutics by 99.3% during the fourth quarter. Millennium Management LLC now owns 1,854,620 shares of the company’s stock valued at $244,000 after acquiring an additional 924,199 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Biora Therapeutics during the 1st quarter worth approximately $118,000. Institutional investors and hedge funds own 24.79% of the company’s stock.
Biora Therapeutics Company Profile
Biora Therapeutics, Inc, a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases.
- Five stocks we like better than Biora Therapeutics
- The How and Why of Investing in Gold Stocks
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- Stock Analyst Ratings and Canadian Analyst Ratings
- 5 reasons TJX Companies will hit new highs in 2024
- Canada Bond Market Holiday: How to Invest and Trade
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for Biora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.